Status:
COMPLETED
Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant...
Eligibility Criteria
Inclusion
- Inform consent
- Male and female, age between 18 and 65 years.
- Naïve to any atypical antipsychotic
- A diagnosis of major depressive disorder
Exclusion
- No use of fluvoxamine
- Patients with a history of bipolar I or II disorder
- Diagnosis of psychotic major depression disorder
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00733668
Start Date
March 1 2006
End Date
November 1 2007
Last Update
March 25 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bruges, Belgium
2
Research Site
Leuven, Belgium
3
Research Site
Liège, Belgium
4
Research Site
Sint-Truiden, Belgium